9,172
Participants
Start Date
September 30, 2009
Primary Completion Date
May 31, 2011
Study Completion Date
April 30, 2012
Trivalent inactivated influenza vaccine High Dose
0.5 mL, Intramuscular
Trivalent inactivated influenza vaccine
0.5 mL, Intramuscular
Rochester
Jefferson Hills
Pittsburgh
Upper Saint Clair
Erie
Penndel
Downingtown
Greenbelt
Columbia
Elkridge
Fredericksburg
Williamsburg
Winston-Salem
High Point
Cary
Raleigh
Raleigh
Salisbury
Charlotte
Hickory
Clinton
Goose Creek
Anderson
Greer
Stockbridge
Jacksonville
Jacksonville
Melbourne
Pembroke Pines
Miami
Coral Gables
South Miami
Cutler Bay
Deerfield Beach
Clearwater
Clearwater
Pinellas Park
Sarasota
Crystal River
Inverness
Celebration
Birmingham
Nashville
Bristol
Columbus
Columbus
Columbus
Cleveland
Akron
South Bend
Dubuque
Marshfield
Chaska
Edina
Fargo
Missoula
Chicago
Peoria
St Louis
Prairie Village
Overland Park
Lexena
Lenexa
Arkansas City
Newton
Wichita
Omaha
Metairie
Norman
Fort Worth
Houston
Galveston
San Antonio
Aurora
Colorado Springs
Colorado Springs
Salt Lake City
Phoenix
Phoenix
Mesa
Scottsdale
Tempe
Glendale
Las Vegas
Los Angeles
Oceanside
Fountain Valley
Santa Rosa
Sacramento
Portland
Corvallis
Lakewood
Milford
Ridgefield
Brockton
Haverhill
San Juan
Toa Baja
Lead Sponsor
Sanofi
INDUSTRY